ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
暂无分享,去创建一个
T. Molina | B. Coiffier | H. Tilly | É. Lepage | F. Reyes | P. Morel | G. Laurent | P. Lederlin | P. Brice | A. Bosly | G. Ganem | C. Fermé
[1] K. Medhi. ACVBP Versus CHOP Plus Radiotherapy for Localized Aggressive Lymphoma , 2006, Indian Journal of Medical and Paediatric Oncology.
[2] J. Earle,et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Dirk Hasenclever,et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. , 2004, Blood.
[4] P. Gaulard,et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. , 2003, Blood.
[5] T. Molina,et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.
[6] E. Jaffe. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .
[7] R. Fisher,et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Raemaekers,et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. , 2003, The New England journal of medicine.
[9] John M Bennett,et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Molina,et al. Factors predictive of early death in patients receiving high‐dose CHOP (ACVB regimen) for aggressive non‐Hodgkin's lymphoma: a GELA study , 2002, British journal of haematology.
[11] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[12] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[13] R. Gascoyne,et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Miller,et al. Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. , 2001, Blood.
[15] J. Byrd,et al. Non‐hodgkin's lymphomas , 2010, Bone Marrow Transplantation.
[16] B. Coiffier,et al. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Taylor Murray,et al. Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.
[18] S. Pileri,et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. , 1999, Blood.
[19] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Fisher,et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.
[21] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[22] J. Connors,et al. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[24] K. Lennert,et al. Updated Kiel classification for lymphomas , 1989, The Journal of pathology.
[25] J. Connors,et al. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. , 1987, Annals of internal medicine.
[26] E. Freireich,et al. Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types , 1980, Cancer.
[27] L. Prosnitz,et al. Results of radiotherapy in control of stage I and II non‐Hodgkin's lymphoma , 1979, Cancer.
[28] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[29] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .